Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Weighted Average and Diluted) (2020 - 2026)

Aytu Biopharma has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$1.05 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 275.0% to -$1.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 through Dec 2025, down 42.86% year-over-year, with the annual reading at -$5.11 for FY2023, 93.1% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$1.05 for Q4 2025 at Aytu Biopharma, down from -$0.08 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.21 in Q1 2025 and troughed at -$35.9 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.77 (2021), against an average of -$4.77.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 6117.14% in 2021 and then surged 140.38% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$8.74 in 2021, then soared by 75.4% to -$2.15 in 2022, then soared by 105.12% to $0.11 in 2023, then tumbled by 354.55% to -$0.28 in 2024, then plummeted by 275.0% to -$1.05 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EPS (Weighted Average and Diluted) are -$1.05 (Q4 2025), -$0.08 (Q3 2025), and $0.21 (Q1 2025).